NCT02852395View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-48816274

PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

August 13, 2016

Primary Completion Date

May 2, 2018

Study Completion Date

May 2, 2018

Conditions
Healthy
Interventions
DRUG

JNJ-48816274

Oral dose; dose range of 5 mg up to 250 mg

DRUG

Placebo

Oral dose; appearance matched to JNJ-48816274

Trial Locations (2)

Unknown

Guildford

United Kingdom

Sponsors
All Listed Sponsors
lead

Janssen-Cilag International NV

INDUSTRY